Early evidence links some Alzheimer’s Disease medications to small cognitive gains in children with autism and low IQ, ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Combining memantine with an older, widely used AD drug further improves measures of cognition, global well-being, activities of daily living, and behavior in people with moderate to severe AD, ...

Forest Laboratories announced that it has submitted a New Drug Application (NDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER), a receptor antagonist and donepezil HCl, ...

Forest Laboratories, Inc., reported last week that patients with moderate to severe Alzheimer's disease taking memantine and donepezil had significant improvement over patients on donepezil alone on ...

In the Treatment of Alzheimer’s Disease, Polypharmacy Increases Across Lines of Therapy, According to New Analysis from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one ...

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults. Last reviewed: 20 June 2018. This ...

Combinations of drugs approved to treat Alzheimer's disease (AD) were tested in older rabbits with delay eyeblink classical conditioning, a form of associative learning severely impaired in AD. In ...

In patients with mild to moderately severe AD (26 ≥ MMSE ≥ 10), donepezil dominates no treatment from both the GKV/SPV perspective, with savings averaging €7,007 per patient (€7,323 undiscounted).